TNF and age-related macular degeneration: To substantiate our approach, it is important to note that there are several ongoing clinical trials testing immunotherapy for AMD, including treatments that target TNF-α (one of the key effector molecules upregulated by CEP) and mTOR (the molecular target of rapamycin) [8].